AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24001080
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) midazolam
Trial: 24001080
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) lorazepam
Trial: 18302621
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instruction/chlorhexidine + cetyl pyridinium gargling
Trial: 16569890
Drug: Ritonavir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (100 mg BID) with fosamprenavir (700 mg BID)
Trial: 16569890
Drug: Ritonavir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (100 mg BID) with amprenavir (600 mg BID)
Trial: 16569890
Drug: Fosamprenavir (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosamprenavir (700 mg BID) alone
Trial: 16569890
Drug: Amprenavir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir (600 mg BID) alone
Trial: 11185675
Drug: Digoxin 0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.375 mg plus 8 mg rosiglitazone
Trial: 11185675
Drug: Digoxin 0.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.375 mg plus matching placebo
Trial: 1316077
Drug: Lomefloxacin 400
RxNorm normalized name: lomefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin 400 mg once daily for 10-14 days
Trial: 1316077
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg every 12 hours for 10-14 days
Trial: 22154198
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment for 6 months, titrated to 40 mg/d
Trial: 18083750
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no atorvastatin treatment)
Trial: 9052303
Drug: Infusion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion group (Group I, n = 6)
Trial: 9052303
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection group (Group II, n = 9)
Trial: 3512534
Drug: Imipramine up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine up to 200 mg/day (mean = 130 mg/day)
Trial: 3512534
Drug: 12 weekly
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weekly therapist‐assisted in vivo exposure sessions (flooding)
Trial: 29704557
Drug: Mabfilin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mabfilin and Fabfilin molecules
Trial: 16282697
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg/day from 2 days after surgery
Trial: 14662211
Drug: Corticosteroids (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (intravenous methylprednisolone 125 mg followed by oral prednisone taper: 40 mg for 1 day, 20 mg for 3 days, 10 mg for 3 days, 5 mg for 7 days)
Trial: 3519097
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg fipexide daily
Trial: 27449221
Drug: Kunxian capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kunxian capsules (0.6 g, three times per day) for 12 weeks
Trial: 27449221
Drug: Kunxian capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kunxian capsules
Trial: 18427362
Drug: Conventional quadrant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional quadrant therapy
Trial: 16167471
Drug: Synbiotic 2000
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic 2000 (four different lactobacilli preparations with 10^10 CFU and prebiotics)
Trial: 12598350
Drug: Alternating regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating regimen (docetaxel 100 mg/m2, doxorubicin 75 mg/m2, cycle-by-cycle alternating)
Trial: 12598350
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen (docetaxel 100 mg/m2, doxorubicin 75 mg/m2, sequential for four cycles)
Trial: 10492276
Drug: 99mTc DTPA
RxNorm normalized name: DTPA
DrugBank: Pentetic acid (DB14007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 99mTc DTPA aerosol inhalation lung scintigraphy
Trial: 7369913
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefaclor
Trial: 6357076
Drug: Carboxypenicillin-aminoglycoside combination
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carboxypenicillin-aminoglycoside combination
Trial: 31215755
Drug: Verubecestat (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verubecestat (100 mg single dose or 30, 80, and 120 mg multiple doses once daily for 28 days)
Trial: 18780164
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release formulation with immediate release element
Trial: 18780164
Drug: Four formulations
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four formulations of Galantamine
Trial: 10695942
Drug: Metronidazole 250
RxNorm normalized name: metronidazole 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 250 mg plus Amoxicillin 500 mg (M+A)
Trial: 29695370
Drug: Hinge Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hinge Health digital care program for chronic knee pain (12-week intervention including sensor-guided exercise therapy, education, cognitive behavioral therapy, weight loss, and psychosocial support)
Trial: 22052584
Drug: Febuxostat 240
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 240 mg
Trial: 18975369
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 or 100 mg)
Trial: 18975369
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 mg (impaired renal function)
Trial: 18975369
Drug: Febuxostat 120
RxNorm normalized name: Febuxostat 120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 120 mg (impaired renal function)
Trial: 18975369
Drug: Febuxostat 240
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Febuxostat 240 mg (impaired renal function)
Trial: 18975369
Drug: Allopurinol 100
RxNorm normalized name: allopurinol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 100 mg (impaired renal function)
Trial: 16472565
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 500 mg twice a day for 5 days
Trial: 28840615
Drug: Curcumin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1 g/day)
Trial: 17953475
Drug: Olmesartan medoxomil/HCTZ
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil/HCTZ (40/12.5 mg/day for 4 weeks; then 40/25 mg/day for 4 weeks)
Trial: 17953475
Drug: Benazepril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril plus amlodipine besylate (20/5 mg/day for 4 weeks; then 20/10 mg/day for 4 weeks)
Trial: 11209625
Drug: Combination prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination prostaglandin E2 (PGE2) gel and Foley catheter
Trial: 9573676
Drug: Delayed intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed intensification therapy
Trial: 9573676
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment without delayed intensification therapy
Trial: 18215600
Drug: Higher-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose statin therapy
Trial: 18215600
Drug: Standard-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose statin therapy
Trial: 12541393
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of doktarin ps cream (DC)
Trial: 12541393
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of ketoconazole cream (KEC)
Trial: 12541393
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of clotrimazole ung (CU)
Trial: 12541393
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of thymol alcohol (TA)
Trial: 12541393
Drug: Systematic intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic intermittent impulsive treatment
Trial: 12541393
Drug: Compound azoles
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound azoles drugs
Trial: 9057377
Drug: Ampicillin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (100 mg/kg/day)
Trial: 9057377
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of benzyl penicillin (100,000 units/kg/day) and chloramphenicol (100 mg/kg/day)
Trial: 6684446
Drug: Thymostimulin (TP‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymostimulin (TP‐1 Serono) in combination with antibiotic therapy
Trial: 24342685
Drug: Monensin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monensin (18 g of monensin/t of dry matter)
Trial: 22340476
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave treatment (ESWT), 20,000 shock wave impulses in 10 sessions over a two-week period
Trial: 15758533
Drug: Clofibrate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibrate (100 mg/kg) plus phototherapy
Trial: 10070909
Drug: Pentoxifylline (PTF)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTF) 400 mg daily for 6 months
Trial: 1963125
Drug: High-soluble-fibre diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-soluble-fibre diet (5 g guar gum thrice daily)
Trial: 1963125
Drug: High-glucose diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-glucose diet (500 ml glucose drink providing 100 g glucose per day)
Trial: 31174239
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC alternating with vincristine and irinotecan, with early radiation therapy (RT) at week 4 concurrent with irinotecan in the experimental arm.
Trial: 26553448
Drug: HDM SLIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM SLIT tablet 6 SQ HDM
Trial: 26553448
Drug: HDM SLIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDM SLIT tablet 12 SQ HDM
Trial: 17513690
Drug: Weekly automated
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly automated telephone disease management (ATDM)
Trial: 17513690
Drug: Monthly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly group medical visits
Trial: 16243128
Drug: Fluconazole 6
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 6 mg/kg per day for 3 weeks followed by 3 weeks of placebo
Trial: 16243128
Drug: Fluconazole 6
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 6 mg/kg per day for 6 weeks
Trial: 16243128
Drug: Griseofulvin 11
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin 11 mg/kg per day for 6 weeks
Trial: 14598620
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine and i.v. clonidine 1 microgram.kg‐1 (CLO group)
Trial: 10766467
Drug: C+E (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E (5 mg x kg(‐1) caffeine and 1 mg x kg(‐1) ephedrine)
Trial: 10766467
Drug: C+E (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E (4 mg x kg(‐1) caffeine and 1 mg x kg(‐1) ephedrine)
Trial: 10766467
Drug: C+E (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E (4 mg x kg(‐1) caffeine and 0.8 mg x kg(‐1) ephedrine)
Trial: 10766467
Drug: C+E (lowest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E (lowest dose: 4 mg x kg(‐1) caffeine and 0.8 mg x kg(‐1) ephedrine)
Trial: 10766467
Drug: C+E (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E (all doses)
Trial: 1481117
Drug: Continuous hyperfractionated
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperfractionated accelerated radiotherapy combined with chemotherapy (20 mg mitomycin C/m2 on day 5)
Trial: 29381191
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (InO) at a starting dose of 1.8 mg/m2/cycle (0.8 mg/m2 on day 1 and 0.5 mg/m2 on days 8 and 15 of a 21- to 28-day cycle, ≤6 cycles)
Trial: 22578498
Drug: Levetiracetam (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (low dose)
Trial: 17653020
Drug: Amiodarone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (300 mg IV over 30 min, then 20 mg/kg/24 h if needed)
Trial: 17653020
Drug: Procainamide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procainamide (1 gm IV bolus, then 2 mg/min for 24 h if needed)
Trial: 10443734
Drug: Neoadjuvant LHRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant LHRH analogue treatment (n = 50)
Trial: 7878758
Drug: Once-a-day cyclosporine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-a-day cyclosporine (CsA) dosing
Trial: 7878758
Drug: b.i.d. cyclosporine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. cyclosporine (CsA) dosing
Trial: 466592
Drug: BCG (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (120 mg) given orally at weekly intervals for 1 month, every 2 weeks up to 3 months, then every 3 months until 18 months
Trial: 466592
Drug: BCG (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG (120 mg) given orally
Trial: 30704504
Drug: Transcranial pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial pulsed electromagnetic fields (T-PEMF) treatment (30 min/day, 50 Hz, ±50 V, 3 ms squared pulses) for 8 weeks
Trial: 30704504
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (sham stimulation, 30 min/day) for 8 weeks
Trial: 30704504
Drug: Transcranial pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial pulsed electromagnetic fields (T-PEMF) treatment
Trial: 25518956
Drug: Nutritional support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional support including a family maize supplement provided to participants.
Trial: 22307831
Drug: PEG‐IFN treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN treatment
Trial: 19391540
Drug: Prozac capsule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prozac capsule, 20 mg/d
Trial: 19391540
Drug: Electroacupuncture for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture for 30-40 min, needle retained for 1 h, once daily
Trial: 19391540
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Prozac and electroacupuncture
Trial: 12019085
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg i.v. once daily followed by oral 400 mg for 7 to 14 days)
Trial: 12019085
Drug: Co-amoxiclav (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amoxiclav (1.2 g i.v. three times a day followed by oral 625 mg three times a day, with or without clarithromycin)
Trial: 7298924
Drug: Doxepin hydrochloride
RxNorm normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin hydrochloride (5% solution)
Trial: 7298924
Drug: Amitriptyline hydrochloride
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline hydrochloride (5% solution)
Trial: 7298924
Drug: Diphenhydramine (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (5% solution)
Trial: 25689529
Drug: Cotrimoxazole lock
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole lock solution (10 mg/ml cotrimoxazole and 2500 U/ml heparin)
Trial: 25689529
Drug: Heparin (2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (2500 U/ml)
Trial: 23134549
Drug: omega-3 polyunsaturated
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 polyunsaturated fatty acids (PUFAs) (3 g, 12 h before PCI) plus standard treatment (n = 43)
Trial: 23134549
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (control group) (n = 47)
Trial: 11146078
Drug: Intraperitoneal cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cisplatin-based chemotherapy (IPCT) 100 mg/m²
Trial: 11146078
Drug: Intravenous cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisplatin-based chemotherapy (IVCT) 50 mg/m²
Trial: 8282275
Drug: Monosodium L‐glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium L‐glutamate (MSG) doses of 1.5, 3.0 and 3.15 g/person
Trial: 3552457
Drug: Alcoholic lignocaine
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcoholic lignocaine (5%) spray
Trial: 3552457
Drug: Aqueous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous lignocaine (5%) spray
Trial: 3552456
Drug: Aqueous cinchocaine
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous cinchocaine (2%) spray
Trial: 29286865
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) with corticosteroids in a fixed tapering regime
Trial: 19950239
Drug: Epoetin‐beta 30,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin‐beta 30,000 U administered s.c. q.w. (group A)
Trial: 19950239
Drug: Reduced ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reduced ribavirin dose of 600 mg daily (group B)
Trial: 16190792
Drug: Sertraline (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (daily dose range between 25 and 100 mg)
Trial: 7491646
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of dextroamphetamine orally every fourth day for 10 sessions paired with physical therapy
Trial: 7491646
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally every fourth day for 10 sessions paired with physical therapy
Trial: 1976487
Drug: Albuterol 200
RxNorm normalized name: ALBUTEROL 200MCG CAP,INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 200 micrograms via MDI
Trial: 7002949
Drug: Oral 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 0.1 N HCl
Trial: 7002949
Drug: Oral 30
RxNorm normalized name: Aloral 300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 30 g glucose
Trial: 7002949
Drug: Oral glucose-acid
RxNorm normalized name: ascorbic acid / glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose-acid combination
Trial: 7002949
Drug: Intraduodenal 20
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRADUODENAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal 20 g glucose
Trial: 7002949
Drug: Intraduodenal 75
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRADUODENAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal 75 cc 0.1 N HCl
Trial: 7002949
Drug: Intraduodenal glucose-acid
RxNorm normalized name: ascorbic acid / glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose-acid combination
Trial: 7002949
Drug: Oral glucose-acid
RxNorm normalized name: ascorbic acid / glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose-acid load